Biotech Experts Will Lead HMHs New Center for Discovery and Innovation   
Make an Appointment

Biotech Experts Will Lead HMHs New Center for Discovery and Innovation

What you need to know

Sol J. Barer, Ph.D., has been appointed as chair of the Board of Directors and David S. Perlin, Ph.D., as chief scientific officer.

More About the Center for Discovery and Innovation

The goal of CDI is to encourage the development of intellectual property with the intent of developing downstream products or technologies that will improve patient care.

Research innovation developed at CDI will lead to the development of opportunities for out-licensing and commercial partnerships.

CDI is an academic-based entrepreneurial center that harnesses innovation from a new renaissance in biomedical sciences to restore patient health and is comprised of three specialty areas:

  • The Institute for Cancer and Infectious Diseases (iCID), where new ways to treat life-threatening infections and cancer at the molecular level are being developed
  • The Institute for Multiple Myeloma (iMM), which will build on the network’s program, one of the world’s largest with more than 2,000 patients on active therapy
  • The Institute for Regenerative Medicine (iRG), where revolutionary therapies will help diseased and damaged tissue heal itself

More About Sol J. Barer, Ph.D.

Dr. Barer was named chair of the Board of Directors for CDI. He is a biotechnology industry veteran and the founder and former chairman, president, COO and CEO of Celgene Corporation.

He serves as chair of the Board of Directors of Teva Pharmaceuticals. He also serves as board chair of Aevi Genomics and Centrexion Therapeutics, and serves on the Board of Directors of Contrafect as lead director. He is also managing partner at SJ Barer Consulting.

“The Center for Discovery and Innovation encourages critical advances in medicine by bringing together today’s best and brightest to enhance patient outcomes. As chair of the Board of Directors, I look forward to transforming biomedical research by empowering innovation.”

Dr. Barer Sol J. Barer

More about David S. Perlin, Ph.D.

Dr. Perlin is the founding chief scientific officer and senior vice president at CDI. He is a highly accomplished biomedical researcher and a global leader in antifungal drug resistance, molecular diagnostics and drug discovery.

Dr. Perlin is the former executive director of the Rutgers New Jersey Medical School’s Public Health Research Institute (PHRI) and former director of the Rutgers Regional Biocontainment Laboratory, one of 13 National Institutes of Health (NIH)-designated national centers for pathogen research.

We use cookies to improve your site experience. By using this site,
you agree to our Terms & Conditions. Also, please read our Privacy Policy. Accept All CookiesLearn More